Safety experience with caspofungin in pediatric patients

Pediatr Infect Dis J. 2009 Dec;28(12):1132-5. doi: 10.1097/INF.0b013e3181af5a15.

Abstract

We analyzed the caspofungin safety experience in 5 clinical registration studies in 171 pediatric patients, 1 week to 17 years of age. Caspofungin was administered for 1 to 87 (mean 12.1) days. The most common drug-related adverse events were fever, increased AST, increased ALT, and rash; few events were serious or required treatment discontinuation. Caspofungin was well tolerated in this pediatric population.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antifungal Agents / adverse effects*
  • Antifungal Agents / therapeutic use
  • Caspofungin
  • Child
  • Child, Preschool
  • Clinical Trials as Topic
  • Echinocandins / adverse effects*
  • Echinocandins / therapeutic use
  • Humans
  • Infant
  • Infant, Newborn
  • Lipopeptides
  • Mycoses / drug therapy*
  • Prospective Studies

Substances

  • Antifungal Agents
  • Echinocandins
  • Lipopeptides
  • Caspofungin